36 Participants Needed

Combination Therapy for Breast Cancer

Recruiting at 13 trial locations
ST
KL
JO
JM
MR
SB
JH
PW
Overseen ByPatrick W Cobb, MD, FACP
Age: 18+
Sex: Any
Travel: May Be Covered
Trial Phase: Phase 1 & 2
Sponsor: BriaCell Therapeutics Corporation
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial requires a 'washout' period (time without taking certain medications) of 3 weeks before starting, and 8 weeks for some specific drugs. You should also avoid any medications listed as prohibited in the trial protocol.

What data supports the effectiveness of the drug combination therapy for breast cancer?

Research shows that combining immune checkpoint inhibitors, like those targeting PD-1, with other treatments can enhance the immune system's ability to fight breast cancer, especially in aggressive types like triple-negative breast cancer. This approach has shown promise in improving outcomes when used alongside chemotherapy or other targeted therapies.12345

What safety data exists for the combination therapy for breast cancer?

The research articles provided do not contain specific safety data for the combination therapy involving Retifanlimab or its other names for breast cancer or other conditions.36789

What makes the combination therapy for breast cancer involving Retifanlimab and SV-BR-1-GM unique?

This combination therapy is unique because it involves Retifanlimab, a drug that blocks a specific protein (PD-1) on immune cells, potentially enhancing the body's immune response against cancer cells. Retifanlimab has been approved for other cancers, like Merkel cell carcinoma, and its use in combination with SV-BR-1-GM for breast cancer represents a novel approach to potentially improve treatment outcomes by targeting immune pathways.810111213

What is the purpose of this trial?

This is an open-label, phase I/II double arm study of the SV-BR-1-GM regimen in combination with retifanlimab in patients with metastatic or locally recurrent breast cancer who have failed standard therapy.Patients will receive the SV-BR-1-GM regimen with combination immunotherapy. There will be an initial evaluation of the combination of the SV-BR-1-GM regimen with retifanlimab every 3 weeks. If this is found to be safe and well tolerated in a cohort of at least 12 patients (dose-limiting toxicities (DLTs) in less than 30% of the patients evaluated), then an expansion cohort of up to 24 patients will be treated with that combination. These will be randomized to two regimens differing in the timing of checkpoint inhibitor administration.

Research Team

GE

George E Peoples, MD, FACS

Principal Investigator

LumaBridge LLC

Eligibility Criteria

This trial is for women over 18 with Stage IV triple-negative breast cancer that can't be treated locally and who have survived past standard therapies. They must expect to live at least 4 more months, not have severe psychiatric issues or major medical conditions, no recent immunosuppressive treatments, vaccines, transplants, or autoimmune disease treatments.

Inclusion Criteria

My cancer is not HER2 positive.
My cancer is in Stage IV.
My recurring cancer cannot be treated with surgery or radiation.
See 3 more

Exclusion Criteria

I have been treated for an autoimmune disease in the last 2 years.
I have a history of colitis.
I have severe psychiatric or major medical issues.
See 8 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

4 weeks
1 visit (in-person)

Treatment

Participants receive the SV-BR-1-GM regimen with retifanlimab every 3 weeks, with safety evaluations and imaging studies performed periodically

12 months
Every 3 weeks (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, with survival analysis every 3 months

5 years
Every 3 months (phone call)

Treatment Details

Interventions

  • Retifanlimab
  • SV-BR-1-GM
Trial Overview The study tests the SV-BR-1-GM regimen combined with retifanlimab on patients with advanced breast cancer. Initially tested on a small group for safety and tolerability; if successful, expanded to more patients randomized into two groups based on treatment timing.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: SV-BR-1-GM, retifanlimab combination original sequenceExperimental Treatment4 Interventions
Subjects will be treated with the SV-BR-1-GM regimen in combination with retifanlimab with cycles every 3 weeks
Group II: SV-BR-1-GM, retifanlimab combination alternative sequenceExperimental Treatment4 Interventions
Subjects will be treated with the SV-BR-1-GM regimen in combination with retifanlimab as follows: Cycle 1: SV-BR-1-GM only Cycle 2: resume retifanlimab on Day 2±1 Cycle 3 and beyond: retifanlimab can be administered on Day -2, Day 0, 1, 2, or 3.

Retifanlimab is already approved in United States for the following indications:

🇺🇸
Approved in United States as Zynyz for:
  • Merkel cell carcinoma

Find a Clinic Near You

Who Is Running the Clinical Trial?

BriaCell Therapeutics Corporation

Lead Sponsor

Trials
4
Recruited
480+

LumaBridge

Industry Sponsor

Trials
5
Recruited
380+

Cancer Insight, LLC

Industry Sponsor

Trials
10
Recruited
520+

LumaBridge

Collaborator

Trials
6
Recruited
410+

Findings from Research

In a mouse model of breast cancer, combining the anti-PD-1 antibody with zoledronic acid (ZA) resulted in a stronger anti-tumor response compared to either treatment alone, indicating a potential synergistic effect.
The combination therapy showed no obvious toxicity, suggesting it could be a safe and effective approach for enhancing breast cancer treatment.
PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.Li, Y., Du, Y., Sun, T., et al.[2019]
Immunotherapy, particularly using monoclonal antibodies that target immune checkpoint receptors, has shown significant promise in improving outcomes for breast cancer patients, especially those with triple-negative breast cancer.
The combination of atezolizumab and nab-paclitaxel as a first-line treatment for metastatic triple-negative breast cancer resulted in notable improvements in progression-free survival compared to chemotherapy alone, suggesting that combining therapies may enhance effectiveness.
Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading.Force, J., Leal, JHS., McArthur, HL.[2022]
Checkpoint immunotherapy is being explored as a new treatment for metastatic breast cancer, but single-agent therapies targeting PD1/PD-L1 or CTLA-4 have shown limited effectiveness.
Combining immunotherapy with other treatments like chemotherapy, radiotherapy, and targeted therapies may enhance cancer immunity and improve treatment outcomes, with ongoing clinical trials investigating these combination strategies.
Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer.Liu, ZB., Zhang, L., Bian, J., et al.[2020]

References

PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model. [2019]
Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading. [2022]
Combination Strategies of Checkpoint Immunotherapy in Metastatic Breast Cancer. [2020]
Immune targeting in breast cancer. [2022]
Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. [2022]
Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer. [2023]
Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis. [2022]
IOLite: phase 1b trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer. [2022]
Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer. [2019]
Retifanlimab: First Approval. [2023]
11.United Statespubmed.ncbi.nlm.nih.gov
A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors. [2022]
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. [2022]
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security